Table 4.
2,8-Dihydroxyadenine-to-creatinine ratio in first morning void urine samples baseline and at the completion of allopurinol and febuxostat treatment periods.
| Patient | Baseline | Allopurinol | Febuxostat |
|---|---|---|---|
| DHA/Cr (mg/mmol) | DHA/Cr (mg/mmol) | DHA/Cr (mg/mmol) | |
| 1 | 12.5 | 4.4 | 0.9* |
| 2 | 22.8 | 7.0 | ND |
| 3 | 34.5 | 5.4 | 1.1* |
| 4 | 8.2 | 2.8 | 0.8* |
| 5 | 17.4 | 8.4 | 1.1* |
| 6 | 13.9 | 5.6 | ND |
| 7 | 15.2 | 1.1* | ND |
| 8 | 16.9 | 5.1 | ND |
Abbreviations: Cr, creatinine; DHA, 2,8-dihydroxyadenine; ND, not detectable (limit of detection <20 ng/mL).
*
Below limit of quantification (<100 ng/mL).